Loading clinical trials...
Loading clinical trials...
ZhenQi FuZheng granules has been used to improve the immune function of human body, protect the bone marrow and adrenal cortex function and promote the recovery of positive function in traditional Chinese medicine care, especially with the immune imbalance diseases like post-surgery, chemotherapy and rhinitis. This project intends to establish AR（allergic rhinitis）specimen library, cell and animal model experiment, combining clinical cohort research with applied basic research, further assess the therapeutic mechanism of ZhenQiFuZheng granules in AR. We assume that ZhenQi FuZheng granules could cause the metabolic omics changes of nasal inflammatory factors and nasal secretions in AR patients, thus improving the type 2 inflammation level of allergic rhinitis.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
Yes
The First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, China
Start Date
June 1, 2024
Primary Completion Date
June 1, 2025
Completion Date
June 1, 2028
Last Updated
December 9, 2024
40
ESTIMATED participants
ZhenQi FuZheng granules (ShiDaiYangGuang)
DRUG
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
NCT04435990
NCT07427576
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions